Company: MDCXW
Filing Date: 2025-05-05
Form Type: 253G2
Source: 0001062993-25-008440
Chunk: 45

Company: Medicus Pharma Ltd.
Filing Date: 2025-05-05
Form: 253G2
Chunk 45
---
 directors, be reasonably expected to interfere with the exercise of the director's independent judgment.

Our Board has undertaken a review of the independence of each director. Based on information provided by each director concerning his or her background, employment and affiliations, our Board has determined William L. Ashton, Robert J. Ciaruffoli, Barry Fishman, Dr. Larry Kaiser, Frank Lavelle, Dr. Sara R. May, representing six of the seven members of our Board, are "independent" as that term is defined under the Nasdaq Rules. In making this determination, our Board considered the current and prior relationships that each non-employee director has with our company and all other facts and circumstances our Board deemed relevant in determining their independence, including the beneficial ownership of our shares by each non-employee director. Dr. Bokhari is not independent by virtue of being the Company's Chief Executive Officer. Dr. Bokhari is the Chairman of the Board. Robert J. Ciaruffoli acts as independent lead director and will assume the duties of the Chairman as and when required to address any actual or potential conflicts of interest.

Structures and processes are in place to permit our Board to function independently of management, including for purposes of encouraging an objective process for nominating directors and determining executive compensation.

Item 14. Principal Accountant Fees and Services.
Principal Independent Accountant Fees and Services

The aggregate fees billed to us by EisnerAmper LLP, our independent registered public accounting firm since December 19, 2024, and MNP LLP, our independent registered public accounting firm until December 19, 2024, for the indicated services for each of the last two fiscal years were as follows:

| Financial Year        
 Ending                | Audit Fees(1) 
           ($) | Audit-Related 
   Fees(2) ($) | Tax Fees(3) 
         ($) | All Other Fees(4) 
               ($) |
| December 31, 2024 (5) |      $168,000 |            $0 |          $0 |                $0 |
| December 31, 2024 (6) |      $134,673 |       $36,114 |     $10,213 |            $9,471 |
| December 31, 2023 (7) |      $158,004 |       $12,125 |      $8,178 |                $0 |

<div align='center'>29</div>

Notes:

(1)Audit Fees include fees for performance